↓ Skip to main content

Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers

Overview of attention for article published in Molecular Cancer Therapeutics, May 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
9 tweeters

Readers on

mendeley
1 Mendeley